Figure 10.

Alda-1 treatment of SCI decreases 4-HNE load and enhances the activity of ALDH2 in the chronic phase (30 days) of a mouse model of SCI.

Like in Figure 4, two different doses of Alda-1 were used to show that daily treatment of 10 mg/kg dose was remarkably effective to reduce 4-HNE load. Western blot (A) and densitometry (B). Measurement of ALDH2 activity (C), western blot of ALDH2 (D), and densitometry (E). Data are presented as the mean ± SD (n = 7). *P < 0.05, ***P < 0.001, vs. Sham; ++P < 0.01, +++P < 0.001, vs. SCI (one-way analysis of variance with Tukey’s post hoc test). 4-HNE: 4-Hydroxy-trans-2-nonenal; Alda-1: N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide; ALDH2: aldehyde dehydrogenase 2; ns: not significant; SCI: spinal cord injury.